S. Williams

发表

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

A. Polliack, Y. Ilan, H. Golomb, 1991, Leukemia & lymphoma.

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2009, Leukemia & lymphoma.

Calcineurin and mTOR Inhibitor-Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study.

U. Duffner, J. Parker, M. Abidi, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell mobilization Can the stem cell mobilization technique influence CD34 þ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies

L. Gordon, J. Winter, S. Singhal, 2005 .

Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product.

L. Gordon, J. Winter, S. Singhal, 2015, Clinical lymphoma, myeloma & leukemia.

The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation.

L. Gordon, J. Winter, S. Singhal, 2004 .

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

J. Vose, J. Fay, S. Bhatia, 2003, Blood.

Cancer and Preganancy

J. Bitran, Stephanie F. Williams, S. Williams, 1985 .

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

T. Zimmerman, S. Williams, D. Grinblatt, 1998, Cancer.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

David E. Irwin, S. Jagannath, S. Singhal, 2009, Blood.

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

L. Gordon, J. Winter, S. Singhal, 2013 .

Application of peripheral blood progenitors to dose-intensive therapy of breast cancer

Stephanie F. Williams, S. Williams, 2004, Breast Cancer Research and Treatment.

High-Dose Chemotherapy

Stephanie F. Williams, S. Williams, 1999 .

Coping strategies and psychological distress in cancer patients before autologous bone marrow transplant

P. Mumby, S. Knight, D. Chastain, 1996, Journal of Clinical Psychology in Medical Settings.

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

L. Gordon, J. Winter, S. Singhal, 2007, Cancer.

Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.

U. Duffner, A. Al-Homsi, Kelli A. Cole, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of Physical Condition on Outcomes in Transplant Patients: A Retrospective Data Analysis

T. Rodriguez, K. Andres, B. Wayman, 2020 .

Is there a role for dose-intensive chemotherapy with stem cell rescue in breast cancer?

S. Williams, 2002, Oncology.

What Is the Optimal Timing of Autologous Transplantation for Metastatic Breast Cancer

S. Williams, 2000 .

F‐18 FDG‐PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem‐cell transplantation for relapsed and refractory Hodgkin lymphoma

B. B. Weitner, L. Gordon, J. Winter, 2014, British journal of haematology.

Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer

R. Mick, J. Bitran, S. Myers, 1993, Breast Cancer Research and Treatment.

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .